These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28426702)

  • 1. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
    Talmage GD; Coppes OJM; Javed A; Bernard J
    PLoS One; 2017; 12(4):e0173299. PubMed ID: 28426702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
    Roar M; Illes Z; Sejbaek T
    Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of natalizumab in a Portuguese population.
    Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
    Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
    Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
    Kaunzner UW; Kang Y; Monohan E; Kothari PJ; Nealon N; Perumal J; Vartanian T; Kuceyeski A; Vallabhajosula S; Mozley PD; Riley CS; Newman SM; Gauthier SA
    Mult Scler Relat Disord; 2017 Jul; 15():27-33. PubMed ID: 28641769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab in the pediatric MS population: results of the Italian registry.
    Ghezzi A; Moiola L; Pozzilli C; Brescia-Morra V; Gallo P; Grimaldi LM; Filippi M; G GC;
    BMC Neurol; 2015 Sep; 15():174. PubMed ID: 26407848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
    Pawate S; Wang L; Song Y; Sriram S
    J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
    Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
    Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis.
    Young KL; Brandt AU; Petzold A; Reitz LY; Lintze F; Paul F; Martin R; Schippling S
    Eur J Neurol; 2013 May; 20(5):803-11. PubMed ID: 23369013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.